Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00674947 | A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors | PHASE1 | COMPLETED | 55 | — | — | Jun 1, 2008 | Jun 1, 2011 | Sep 16, 2013 | 3 | United States |
| Name | Type | Description |
|---|---|---|
| BIIB015 | DRUG | IV infusion once every 3 weeks until disease progression or unacceptable toxicity |
Inclusion Criteria * Age 18 years or older at the time of informed consent. * Solid tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic therapy and for which no standard therapy exists. * ECOG Performance Status \</= 2. Exclusion Criteria * History of keratoconjunctivi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |